Loxo buys BTK inhibitor | August 7, 2017 Issue - Vol. 95 Issue 32 | Chemical & Engineering News
Volume 95 Issue 32 | p. 13 | Concentrates
Issue Date: August 7, 2017

Loxo buys BTK inhibitor

Department: Business
Keywords: oncology, BTK inhibitor, leukemia

Loxo Oncology will pay Redx Pharma $40 million for the full rights to an inhibitor of BTK, an enzyme involved in B-cell development. Imbruvica, a B-cell cancer treatment marketed by AbbVie, and other BTK inhibitors in clinical studies all covalently bind to the enzyme, a mechanism Loxo argues drives resistance to those molecules through a specific mutation. By reversibly binding to BTK, Redx’s lead molecule, RXC005, could help people with cancer who no longer respond to the covalent inhibitors. Now known as LOXO-305, the compound is expected to begin human trials next year.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment